Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
Open Access
- 9 June 2009
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 101 (1) , 149-159
- https://doi.org/10.1038/sj.bjc.6605112
Abstract
Background: Methods: Results: Conclusions:Keywords
This publication has 166 references indexed in Scilit:
- Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancersGynecologic Oncology, 2008
- The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancerBritish Journal of Cancer, 2008
- In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathwayBritish Journal of Cancer, 2007
- Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studiesBritish Journal of Cancer, 2006
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- Role of the stress sigma factor RpoS in GacA/RsmA-controlled secondary metabolism and resistance to oxidative stress inPseudomonas fluorescensCHA0FEMS Microbiology Letters, 2005
- How should meta‐regression analyses be undertaken and interpreted?Statistics in Medicine, 2002
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinomaThe Lancet, 2001
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986